Table 1.

Summary of the 5-year efficacy results of CheckMate 067 along with the reported dermatologic adverse events^a.

Study group		Nivolumab plus ipilimumab	Nivolumab	Ipilimumab
Overall survival
	Value, median (months)	>60	36.9	19.9
	HRb	0.52c	0.63d	N/Ae
Progression-free survival
	Value, median (months)	11.5	6.9	2.9
	HR	0.42c	0.53d	N/A
Adverse events (all grade), %		96	87	86
Adverse events (grade ≥3), %		59	23	28
Dermatologic adverse events
	Rash (all grade), %	30	24	22
	Rash (grade ≥3), %	3	<1	2
	Pruritus (all grade), %	36	23	36
	Pruritus (grade ≥3), %	2	<1	<1
	Vitiligo (all grade), %	9	11	5
	Vitiligo (grade ≥3), %	0	<1	0
	Dry skin (all grade), %	5	5	4
	Dry skin (grade ≥3), %	0	0	0
	Maculopapular rash (all grade), %	12	5	12
	Maculopapular rash (grade ≥3), %	2	1	<1

^aAdapted from Larkin et al [5].

^bHR: hazard ratio.

^cNivolumab plus ipilimumab versus ipilimumab.

^dNivolumab versus ipilimumab.

^eN/A: not applicable.